21 Business Park Drive
Branford, CT 06405
United States
(203) 646-6446
https://azitrainc.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 10
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Francisco D. Salva | President, CEO & Director | 427,03k | N/A | 1971 |
Mr. Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, COO & Director | 161,61k | N/A | 1990 |
Mr. Norman Staskey | CFO, Treasurer & Secretary | 314,02k | N/A | 1970 |
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
El ISS Governance QualityScore de Azitra, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.